Curative Biotechnology Inc (ID) (CUBT)

Non-promotional information until there is a press release is a wise move.

CUBT pretty informative. The potential is there for a big success. This is the kind of thing that can keep people interested and investing in between PRs and filings that management needs to do more of.

https://www.linkedin.com/posts/paul-m-michaels_reformulating-diabetes-drug-to-treat-degenerative-activity-7479951170598375424-Peve?utm_source=share&utm_medium=member_android&rcm=ACoAAC5SabIBtz_AOYFB3farfCgsByhy2x4zCeg

Lol Right!! Was hoping the BING would come before the 0

when is the bingo???

I have said that I don't have any inside information. Nothing specific. Just have a vibe for the general path forward. Which has not changed imo.

Yeah that is what I am saying. 1-2 PRs a month keeps things like this from happening. Not saying they all have to be world beater PRs. But just show the company is actively trying to further their business.

What happened to the information you had? I guess they didn’t know what they were talking about? 

I wonder why they're not updating on OTC ID since May 12th?

Need news. They had the stock rolling and ready to go after those first 2 PR's almost 2 months ago. If you go that long without news of any sort?

This is what happens.

FYI no dilution has been taking place so this is retail getting tired/bored.

someone is selling 7K for 1.10

3 - are we getting close?

which NH?

I think we are about to have a BINGO.

AI generated or published article? 

Please share the source link

Curative Biotechnology, Inc. (OTC: CUBT) has structured its recent corporate operations to submit an application to uplist from the base OTC Pink open market to the OTCQB Venture Market.As of June 2026, the specific sequencing, prerequisites, and timeline for Curative's OTCQB application involve the following factors:1. Sequential Application PrerequisitesManagement outlined a strict operational sequence that must occur before the formal application is filed:The Reverse Stock Split (Completed): Curative executed a 1-for-150 reverse stock split. This successfully consolidated its capital structure from ~1.02 billion shares to ~6.8 million shares. The split satisfies the primary market requirement by raising the company’s minimum bid price well above the $0.01 OTCQB minimum requirement (and satisfies the standard $0.05 benchmark).Clinical Supply Agreement (Completed): The company conditionalized the filing on finalizing its drug manufacturing contracts. It checked this box by officially engaging Sterling Pharmaceutical Services to produce its sterile metformin ophthalmic drops.The Filing Threshold: With the manufacturing framework in place, the company’s stated roadmap indicates they are now positioned to submit the official OTCQB upload application.2. OTCQB Compliance & Listing RequirementsTo secure an approved application, Curative must satisfy the ongoing financial and governance benchmarks verified during the OTC Markets application review process:Reporting Compliance: The company must remain fully current in its SEC financial reporting obligations via EDGAR.Corporate Governance: Curative's board must feature at least two independent directors. Its transfer agent must also directly verify the total outstanding shares.Fees & Paperwork: The submission requires an initial $2,500 non-refundable application fee paid to OTC Markets Group, alongside an initial OTCQB Certification signed by the CEO or CFO.3. Intended Market BenefitsMoving the application forward is designed to elevate the stock out of the speculative "Pink sheets" tier. Management's goal for entering the OTCQB Venture Market is to build improved transparency and credibility with retail market participants and institutional biotech investors.

CUBT I really can't say too much on a public message board nor am I am insider, but what I will say is the impression that I have received from the people I talk to within the 'circle of trust' for CUBT leads me to believe that this will be a potential billion dollar bio company if it is not bought out before then.

LOL. Now that's some spin-dancing there...

"A potential billion dollar bio company" that owns nothing other than some licenses on some "orphaned" (ie - abandoned by their original developer due to unprofitability) that they haven't done any sort of substantial R&D on since 2022...

https://www.otcmarkets.com/stock/CUBT/financials

CUBT I really can't say too much on a public message board nor am I am insider, but what I will say is the impression that I have received from the people I talk to within the 'circle of trust' for CUBT leads me to believe that this will be a potential billion dollar bio company if it is not bought out before then.

I have no real reason to doubt them. The last time I felt this good about CUBT was when it was at 007 and went to .25. I think this time, again with the caveat that everything comes together, that run could be childs play compared to what is coming.

Just look how this trades. Imagine they come out with a financing/collab/M&A PR. With this OS? It goes to $50. Probably much more. And imo it is coming.

Please tell us more about the merit. One day remaining this week. It’s time these guys actually get something accomplished. 

IMO CUBT starts to make a major move to the upside in the next week or so. Just my opinion but I don't say that without merit.

Smart.

1. The Global "Bharti" Platform License (PCT/US2020/050540)The foundation of Curative's intellectual property is its exclusive, worldwide license from the National Eye Institute (NEI) for the fundamental discovery titled "Druggable Targets to Treat Retinal Degeneration".International Phase Status: This core invention was processed through an international PCT application, allowing the technology to seek parallel protection across over 150 contracting member countries.National Phase Entry: The recent Canadian patent allowance represents a successful breakthrough from this international pipeline. The underlying application claims priority to the original U.S. filings, enabling Curative to advance national-phase examinations simultaneously within the European Patent Office (EPO) and key Asian markets.

Preclinical Benchwork Base: The company is bypassing early-stage exploratory K9 data by relying on extensive human preclinical research models. They are leveraging the FDA's Minor Uses in Major Species (MUMS) accelerated approval pathway, arguing that the existing human preclinical data provides the "reasonable expectation of effectiveness" required to start an abbreviated 24-dog conditional trial directly.

CUBT. Get ready for a filing which imo takes it to $10 and more. Depending on the BIO stock mania.

OTCID for CUBT today. Next step financing. Next step Nasdaq.

Yeah something is happening. Quote wasn't showing up on my streamer (fidelity) initially (it is now) and OTCID now as well. Very positive.

here we go????

Here we go.... :)

CUBT nice article. I believe this is similar to what Curative is about to embark on but with more added capital to start. Standing by for the coming PR.

https://www.lifescienceleader.com/doc/why-drug-repurposing-might-be-biotech-s-most-capital-efficient-strategy-0001

We were supposed to have lit this rocket, right?

Feels like an Acme special.

Finally CUBT and *MEDH about to lift off!!

Which one first!

CUBT chart is looking good for a change. I noticed the 10K bid too.

CUBT I am in Vegas for the weekend and missed the last part of trading today traveling. Did the ask get heavy at all? Nice close regardless. Did you notice that 10 K bid earlier in the morning? Good to see.

Whatever the origin of the trades, it is following a pattern of OTC stocks that explode... one that we have both certainly seen many times.

I am invariably the one, like you, warning others away at it goes 10-50 fold.

I have a few bucks here, and I'll let it ride.

I have seen 3Flight hit a home run before...

Somebody's playing with the PPS. 13 trades so far, over a 4 to 1 sell to buy ratio, yet the PPS is up. As I said, creating an illusion of interest in the stock.

1.55 x 1.99!

I don't think anyone has claimed otherwise? Not sure why you are making a big deal out of a low float/OS stock gradually rising. All he said was the stock is starting to move. Which it is.

I mean it is better than gradually falling amirite?

All I have said is with the low float and OS. And CUBT being a bio? I have seen 1000, 10,000, even 50,000 percent moves with stocks like this. Will it happen?

Who knows. But signs are definitely starting to point in the positive direction.

But go ahead. Poo poo.

And, once again, 15 trades all day long, 3200 shares. That's it, and hardly any money involved.

Yes. I am sure there are people out there in the Universe that are spending their hard earned dollars on CUBT to slowly and gradually take it up...all for the fun of it. Not for any other valid reason. Just......reasons.


I don't mind a hater. They are actually good for stocks to have. But you have CDS. Curative Derangement Syndrome.

You can make an illiquid stock do whatever you want it to do, and the last 2 "VERY good" PR's were just fluff.

I noticed that you didn't say a word about the last 2 VERY good PR's. But are super quick to poo poo the trading pattern of CUBT. Even though it is moving up.

Yeah, I did. Sorry about that.

Yeah he was talking about me. But in my defense, I think I have a really good track record when it comes to CUBT.

I pumped it back in 2020 and it went from .007 to 23 cents. That is great by any measure.

I bashed the hell out of it in 2023 or so and in the next 2 years it went back down to .004 because I had a 'feeling' it was in a dead zone because of interest rates, new OTC rule changes, and financing for OTC companies went totally dry. It was a no win situation.

I am now VERY positive on CUBT because one...we have a new Sec of Health in charge who loves companies like CUBT. Two...because interest rates are falling or are predicted to fall. Three....because financing for LEGIT OTC companies like CUBT is loosening up. And four....because I think CUBT has a drug port that if successful is now worth multi billions and they are much closer to getting that developed than they ever have been. The US and western world population is aging. Aging means eye issues. CUBT has a potential treatment for that. The dog and pet angle is icing on the cake.

So far from my .004 call it has gone to almost .01 pre RS. Not huge. But ok. I think with the small OS and float (which is why I loved the RS considering it is a bio tech)....if the right things happen? This is a $100 a share stock or more if bio tech/short/drug port mania hits it.

You clearly have me confused with someone else...
He's been claiming to know stuff that wasn't or hasn't come true for quite some time.

To put this into perspective, the stock is still only really trading at around .009 pre RS. This stock has a lonnnnnngggg way to go to the upside to get back to even close to old highs. Which, if they come through this time on their drug portfolio, should be surpassed easily.

I know that is an IF, but if's and CUBT investment gluts were candy and nuts, oh what a Merry Christmas we would have.

Ya never know. But the ask has really thinned out and the bids are growing. Which is always a good sign.

I didn’t take that persons post in the same way but now understand better your perspective
I always appreciate your counter views just not on this one specifically.